ArticleCancers2021
PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- Observational
- Expression of Long Non-Coding RNA-NEAT-1 in Papillary Thyroid Carcinoma in Relation to Immunohistochemical expression of CD8 and PD-L1 as Indicators of Tumor Immune Microenvironment.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2025Article
- Macrophage abundance in oncocytic thyroid cancer is associated with PD-L1 expression.Endocrine oncology (Bristol, England) · 2025Article
- Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.Endocrine · 2024Article
- PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.Endocrine pathology · 2024Article
- The evolving process of ferroptosis in thyroid cancer: Novel mechanisms and opportunities.Journal of cellular and molecular medicine · 2024Review
- Evaluation of CTLA-4 and PD-L1 Expression in Thyroid Carcinoma and Its Prognostic Significance.Cureus · 2024Article
- PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.Molecular oncology · 2024Article
- Article
- Delving into the Role of lncRNAs in Papillary Thyroid Cancer: Upregulation of LINC00887 Promotes Cell Proliferation, Growth and Invasion.International journal of molecular sciences · 2024Article
- Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.Scientific reports · 2023Article
- Relationship between PD-L1 expression and molecular aberrances in lung adenocarcinoma with solid components.Journal of thoracic disease · 2023Article
- Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.Frontiers in endocrinology · 2023Article
- Risk factor analysis and prediction model for papillary thyroid carcinoma with lymph node metastasis.Frontiers in endocrinology · 2023Article
- Combined expression of theGland surgery · 2022Article
- Risk Factors for Cervical Lymph Node Metastasis in Middle Eastern Papillary Thyroid Microcarcinoma.Journal of clinical medicine · 2022Article
- Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma.Endocrine connections · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-L1 inhibition is a promising therapeutic target whose efficacy has been demonstrated in several cancers. Immunohistochemistry was performed to assess PD-L1 protein expression in PTC. We further conducted in vitro analysis to investigate the role of PD-L1 in regulating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.